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This inaugural meeting of the European Science
Foundation’s programme, ‘Integrated Approaches
for Functional Genomics’, was opened by Gianni
Cesareni (University of Rome Tor Vergata), one
of the organisers. He compared proteomics to a
jigsaw, but more difﬁcult because it involves four
dimensions and some of the pieces are still missing.
Ideally, we would like to know the afﬁnity of each
protein for each of its binding partners. This will
require much more work and there are several
complementary approaches.
(i) Most current knowledge of protein-protein
interactions resides in the published literature
but it is not all readily accessible. Various
groups are working on ways to extract this
information and compile databases of protein-
protein interactions (see Brannetti et al., p. 314
and Blaschke et al., p. 310).
(ii) Protein complexes can be isolated from cell
extracts and the components identiﬁed.
(iii) There are experimental means to detect possi-
ble interactions among proteins, eg. yeast two-
hybrid screening, but these do not necessarily
reﬂect what happens inside the cell.
(iv) Characterisation of the speciﬁcity of individual
protein-protein interactions.
(v) Protein interactions may be predicted computa-
tionally, based on structural information.
There are two views of the type of protein
interactions that occur within a cell, which have
different implications for cluster modelling. One sees
a ﬁxed complement of given complexes, with most
proteins existing as multimers: this will give discrete
unique clusters. The other sees many monomers in
constant exchange among different multimeric com-
plexes, which produces extended clusters.
Genetic methods
The ﬁrst formal presentation was given by Pierre
Legrain (Hybrigenics, Paris) who discussed ways of
comparing datasets from large-scale experiments
searching for protein interactions (see Legrain,
p. 310). Three important issues in this area are the
incompleteness of these datasets, the abundance of
false positive results, and the large size of the
datasets, which result in the need for speciﬁc
bioinformatic tools. He explained that the primary
users of protein interaction data are biologists, who
need exploratory tools, such as PIMRider
TM, deve-
loped by Hybrigenics. Other users of the data
are bioinformaticians, who need the data to be
deposited in a convenient, extractable format,
allowing further analysis, such as clustering of
interactions.
He also discussed the issue of regulated access:
Hybrigenics provides PIMRider
TM to academic
laboratories for free, but because they are a
commercial company they have to pay for, or
may even be denied access to, many sources of
data.
Dr Legrain’s group uses the yeast two-hybrid
system to detect protein interactions, whereas Brian
Kay (University of Wisconsin) uses phage display of
libraries of combinatorial peptides (see Kay,
p. 304). He uses this approach to identify peptides
that bind to a chosen target protein and then uses
the consensus among the selected peptides to
predict which protein might bind to the chosen
protein in the cell.
As pointed out by Mike Taussig, this has the
disadvantage of detecting only those interactions
that involve short peptides and are independent
of three-dimensional structure. Many of the
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protein structures, close to proline-rich regions that
disrupt higher-order structure.
The ﬁnal genetic approach to detecting protein
interactions was described by Andreas Plu ¨ckthun
(University of Zurich) who exploits a Darwinian
method of repeated diversiﬁcation and selection for
evolution of antibodies. This can be carried out
in vitro for single selections using ribosome display.
In this approach, the mRNA is completely trans-
lated but the nascent protein remains trapped in the
ribosome complex together with the mRNA; the
protein emerges through the ribosomal tunnel,
whereupon the relevant domain can fold and bind
to a target. The complex is stabilised by addition of
Mg
++. Antibodies are the principal examples to
date of proteins selected by ribosome display. For
those that bind a given target, the mRNA is
isolated and converted back into DNA by reverse
transcription PCR under conditions that allow
errors to be introduced (use of non proof-reading
Taq polymerase); selection is then repeated, looking
for proteins with improved binding afﬁnity. This
PCR-based system, which avoids bacterial trans-
formation, can generate huge libraries very quickly;
each cycle takes one day and libraries of 10
11–10
12
proteins are produced. Greater numbers are possi-
ble, but Dr Plu ¨ckthun said that it is preferable to
perform further rounds of variation and selection
than to increase the size of the library by 100-fold.
The system is compatible with stringent selection
conditions; many people consider ribosomes to be
fragile components but the complexes are reason-
ably robust. This method has been used in
conjunction with the synthetic Human Combina-
torial Antibody Library (HuCAL) [1] to select
antibodies against insulin and a DNA quadruplex
structure. The combination of a synthetic library
and secondary afﬁnity maturation mimics the
versatility of the immune response in vitro.
Selection conditions in ribosome display can be
manipulated to favour certain properties amongst
the newly evolved proteins. For example, for
improved afﬁnity, long off-rate selections (up to
250 hours) are used with biotinylated ligands in
competition with an excess of unlabelled antigen;
since the on-rate of most antibodies falls within a
narrow range, off-rate selection alone produces
antibodies with increased afﬁnity.
Parallel screening of several antibodies and
antigens simultaneously (‘library versus library’)
can be achieved by moving the process inside the
cell, and using growth selection to screen for
interactions in a ‘Protein Fragment Complementa-
tion Assay’ (PCA). The idea is to cut an essential
enzyme in half and allow the two parts to interact
in the cell; reconstitution of the enzyme, in the
correct geometry for activity, is mediated by a
secondary interaction between an antigen and anti-
body. Thus, one half of the DNA encoding the
enzyme, in this case dihydrofolate reductase
(DHFR), is fused to the DNA for a single chain
antibody, while the other half is fused to the DNA
for a potential ligand. Binding of the antibody to
ligand will reunite the halves, restoring enzyme
activity and allowing the cells to grow on minimal
medium. This system was shown to work in
Escherichia coli and to possess the requisite speciﬁ-
city: when a mixture of antigen and antibody DNAs
was used, such that 21 possible double trans-
formants could be made, the only cells that grew
were the three expressing cognate antigen-antibody
pairs. This assay has the advantage of being fast,
with simple handling; no expression or puriﬁcation
of antibody and antigen is necessary and only the
DNA is needed. It also has a very high signal:noise
ratio, with a 10
7 fold difference between cognate
and noncognate pairs. Its limitations are that both
the antigen and the antibody must be stable in the
cytoplasm (Dr Plu ¨ckthun’s group has constructed
such an antibody library by removing disulphide
bonds) and that the length of the linker needs to be
optimised, which has also been done. The PCA
suffers from the same restriction in library size as
phage display, since it involves bacterial trans-
formation, and the proteins must fold correctly in
E. coli, which does not always happen. However,
it will work with individual domains and is
particularly sensitive, because only very small
amounts of DHFR are required to restore growth.
This assay does not select for high afﬁnity binding,
for which ribosome display is better, but does allow
for the simultaneous isolation of several antigen-
antibody interacting pairs.
Peptide and protein chips
This session began with Jens Schneider-Mergener
(Jerini AG, Berlin) describing the SPOT technology
for highly parallel synthesis of peptides, in array
format, on ﬂat surfaces (see Schneider-Mergener,
p. 307). These arrays can then be used for mapping
protein-protein interactions, amongst other uses.
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in this case using chemical mutagenesis to drive the
evolution of new sequences.
The danger, pointed out by Gianni Cesareni, is
that by testing all possible binding interactions
amongst domains, one will ﬁnd a ligand for any
given target but if the natural ligand involves more
than one binding motif, one may never ﬁnd a true
high afﬁnity ligand. Brian Kay suggested synthesis-
ing a complete yeast or bacterial genome for use as
a protein set: this has been considered but not yet
attempted.
DoloresCahill (Max-Planck-Institute of Molecular
Genetics) has exploited the robotics developed by
Hans Lehrach’s group, originally for generation of
high density DNA arrays, and has adapted these to
high-throughput protein analysis. She described the
strategy used to generate high-density arrays of
thousands of proteins from a non-redundant cDNA
library, where each protein is represented only once.
This involves combining three well-known technol-
ogies, ie. cDNA library construction, recombinant
protein expression and high density colony array-
ing. The proteins, which are His-tagged, are
generally expressed from E. coli, but Saccharo-
myces, Pichia pastoris and in vitro expression are
now also being explored. Robots pick bacterial
colonies, array them into microplates and rearray
the library according to selected coordinates onto
PVDF membranes, where expression is induced.
Dr Cahill described work on a cDNA library
prepared from human fetal brain mRNA (chosen
because of the high number of genes expressed in
this tissue compared with other tissues). After
screening for in-frame protein expression using
antibody to the His tag, and characterising clones
using the hybridisation technique of oligonucleo-
tide ﬁngerprinting, a non-redundant UNIgene/
UNIprotein set of about 15,000 clones was gener-
ated. Dr Cahill found an estimated 13,000 singly
represented cDNA sequences, of which 60% repre-
sent full-length clones. Up to 4800 proteins could be
arrayed on a standard microscope slide. Some of
the drawbacks that Dr Cahill pointed out are that
E. coli expression misses membrane proteins and
proteins which are toxic to the bacteria, in addition,
there are no glycosylations or post-translational
modiﬁcations, and the proteins are denatured due
to the conditions used to lyse the E. coli.
Applications of protein microarrays that Dr
Cahill described include screening with antibodies,
to identify the antigen ligand, and screening of
patient sera. In one example, the protein array was
screened with sera from autoimmune patients and
positives were picked out, though the signals were
sometimes weak and better results were obtained on
the redundant set. When a positive is found, the
protein can easily be identiﬁed, by sequencing the
cDNA insert from the bacterial clone. The protein
array is also being used for parallel selection of
antibodies from phage display libraries, from which
antibody arrays are being developed on glass or
PVDF membranes. The aim for antibody arrays is
to produce proﬁles of the proteins expressed in a
given tissue. However, with an estimated 30–40,000
genes in the human genome, Dr Cahill believes that
alternative splicing will produce about 10 times as
many proteins: what fraction of these will be
expressed in any given cell type, or detectable by
the array, is not yet known.
Ian Humphery-Smith (University of Utrecht) is
trying to produce antibody arrays that can be used
to monitor the protein complement of all human
tissues in an integrated approach to health and
disease. The objective is to make a reporter matrix
capable of following the protein output of every
human gene, which will complement DNA array
data on gene expression. The three reasons for
going to an array-based approach to proteomics are
parallelisation, miniaturisation and automation.
Antibody arrays will allow screening of the entire
human proteome, but the antibodies will ﬁrst have
to be produced and then screened against protein
arrays. The traditional approach for assessing anti-
body cross-reactivity involves hybridisation against
a panel of over 200 tissue sections, but most cell
proteins are in low abundance, while most of the
abundant proteins are common to all cells. To
establish their speciﬁcity, antibodies must therefore
be screened extensively on protein (antigen) arrays.
The dilemma is to make antibody arrays relevant in
time and cost of production. To try and obtain
antibodies against every human protein, Dr
Humphery-Smith is immunising mice in parallel
with conserved exons, tagged with an immunogenic
enhancer, which directs the antigen to antigen-
presenting cells. In contrast to Andreas Plu ¨ckthun,
he believes that in vitro technology is not sufﬁcient
to replicate the full repertoire of the immune
system. Because for every human gene there will
be on average 10 products, the proteome is at least
400,000 proteins strong, and to produce antibodies
against that number of antigens by any technology
will be a daunting task; employing the conserved
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gene product families. He believes that to get
relevant antigenicity emulations in the form of
protein arrays with which to screen the antibodies
will take 2–3 years.
The real challenge is to produce antibody arrays
cheaply, which means integrating robotics at each
step in order to process thousands of antibodies
against thousands of protein antigens. To do this,
over the last two years Humphery-Smith’s group
has been developing prototype robotics designed to
process more than 10 million ELISA equivalents
every 2–3 hours. Optimal screening will require
100,000 different recombinant proteins on a chip,
which will not be ready for 2–3 years, but the robot
will be tested at 50,000 ELISA equivalents per day
over the next six months. It is designed to screen
1500 different antibodies against 100,000 antigens
in 100 million ELISA equivalents per day. These
numbers are needed in order to get to grips with
building afﬁnity ligands against the elements on the
human proteome. The objective in fact is to have
ﬁve of these robots operating half a billion ELISA
equivalents per day within the next three years in
Utrecht.
The improvements in protein arrays that are
needed are in the surface chemistry: arrays need a
surface that will bind the antigen and nothing else,
to avoid background and eliminate the need for
blocking and washing. The antigen needs to be held
in conditions that maintain its conformation: plenty
of hydroxyl groups are used to mimic an aqueous
environment. These conditions also need to be
adjustable so that the binding of a given compound,
be it a protein, nucleic acid or chemical ligand, to
the protein array can be titrated. A problem with
yeast two-hybrid assays is that many proteins will
interact to a certain extent with some afﬁnity. The
protein-protein interaction studies now being per-
formed will create vast amounts of data and Dr
Humphery-Smith stressed the need for further
investment in data management, processing and
interrogation techniques.
Since the proteins of perhaps 10% of the genome
cannot be expressed or even cloned, there is a need
for a method to ‘close’ the genome to provide com-
plete coverage. For this Humphery-Smith is identify-
ing ‘signature peptides’, elements within proteins that
have a functional or structural role in protein
interactions; antibodies will be raised against these
sequences as recombinant peptides and then screened
for conformational cross-reactivity against protein
arrays. Finally, he called for support for the newly-
formed Human Proteome Organisation (http://www.
hupo.org/).
Mass spectrometry
The limitations of genome sequence for under-
standing biological function were beautifully illu-
strated by Peter Roepstorff (University of Southern
Denmark, Odense), who asked us to consider a
caterpillar and a butterﬂy: very different organism
phenotypes but with the same genome sequence.
Hence the need to study proteins and one of the
most successful ways of doing this is by using mass
spectrometry, which is central to proteomics and the
qualitative and quantitative large scale analysis of
complex protein mixtures. A second major challenge
is to identify not just the core proteins, but also the
post-translational modiﬁcations (PTMs), such as
glycosylation, phosphorylation and acylation. As a
result of these and other PTMs, current estimates
are that there will be about 10 times as many
molecular protein species as there are genes in a
given organism.
Other issues to be addressed in proteomics include:
(i) Either eliminating the need for protein separa-
tion or ﬁnding an alternative method to 2D
gels, which remain as much an art as a science.
Multidimensional capillary separation is one
possibility, but this has only a fraction of the
separating power of current gels.
(ii) The poor quality of current genome annota-
tion, which may be circumvented by searching
crude genomic sequence using mass spectro-
metry data.
(iii) Quantitation: should this be performed at the
separation stage, comparing spot intensities in
gels, or during mass spectrometry?
(iv) Should protein interaction studies use gel-based
or afﬁnity-based techniques?
Dr Roepstorff termed detection of PTMs
‘modiﬁcation-speciﬁc proteomics’ and introduced a
new ‘omics’ - modiﬁcomics. He described detection
of sites of phosphorylation using mass spectrometry
on proteins isolated with anti-phosphotyrosine
antibodies [3]. With MALDI mass mapping, alkaline
phosphatase treatment directly on the target can be
used to compare spectra to see where phosph-
ate groups have been lost. He has successfully
developed a means of detecting protein nitration, a
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and stress conditions in the cell. In an exploratory
model of in vitro nitration of BSA, Western blotting
with an antibody against nitrotyrosine was used to
loacte the nitrated protein. Nitrated peptides could
be identiﬁed after in-gel digestion and the nitrotyr-
osines identiﬁed by electrospray ionisation mass
spectrometry. This revealed that two peptides were
nitrated, while precursor ion scanning for the
immonium ion for nitrotyrosine revealed two addi-
tional partially nitrated peptides [4] He has also
addressed the complexity of glycosylation, ﬁnding
that c-interferon possesses 13 putative glycan
structures on Asn25 and 18 on Asn97 [6]. Such
complicated glycosylation heterogeneity is prob-
ably important and a way nature uses to ﬁne-tune
interactions. Finally, in the area of protein inter-
actions, Dr Roepstorff has used DNA attached to
magnetic beads as a substrate to isolate DNA-
binding proteins that were then characterised using
MALDI mass spectrometry [2]. His philosophy is
that the study of protein interactions should make
use of all available tools in the hope that the
results will all point in the same direction.
In response to questions, Dr Roepstorff ex-
plained that mass spectrometry can generate
enough peptide sequence data to identify proteins
whose gene sequence is known, while for proteins
whose sequence is not in the databases, enough
information can be obtained by MS/MS for clon-
ing. For de novo sequencing, software programs are
available to help with the interpretation of mass
spectrometry data, although none provide auto-
mated sequencing from the mass spectra.
Benedetta Mattei (University of Rome, La
Sapienza) presented studies combining surface
plasmon resonance with mass spectrometry for the
analysis of protein interactions, that she performed
while working with Peter Roepstorff (see Mattei
et al. next issue). In this approach, surface plasmon
resonance is used to capture peptides interacting
with a chosen protein, which are then identiﬁed by
mass spectrometry. This can be used to map the
domain of a protein that is forming the interaction
surface.
A major development was described by
Carol Robinson (University of Oxford) who has
successfully applied quadrupole time-of-ﬂight (Q-
TOF) mass spectrometry to large complexes held
together solely by non-covalent interactions. This is
not a high-throughput approach but the elegance of
the experiments impressed everyone present. She
uses nanoﬂow electrospray with low volumes in
very small capillaries and allows evaporation to
proceed slowly. A gentle pressure gradient guides
the intact complex across the chamber. Slightly
increasing the amount of energy in the system
causes the complex to break up into its more stable
constituents, providing valuable information about
the probable routes of assembly. Dr Robinson
studied a recently described molecular chaperone,
MtGimC, which was shown to consist of two a and
four b subunits. Further examination showed that
the assembly process was highly cooperative, with
no intermediates being detected.
Dr Robinson has also investigated protein-RNA
interactions, which are stronger than protein-protein
interactions in the gas phase and thus rather more
difﬁcult to study. TRAP is an RNA-binding protein
that was known to bind tryptophan. She showed that
in the absence of tryptophan, 11 TRAP monomers
associate autonomously: addition of tryptophan led
to cooperative binding. She also conﬁrmed the
existence of a 22-mer, which had been postulated
but never proven.
Another experiment looked at the composition of
the E. coli ribosome, a huge complex of three RNA
molecules and 55 different proteins. This can be
maintained intact in the mass spectrometer, but
lowering the Mg
++ concentration causes it to
dissociate into the 50S and 30S subunits. Further
controlled dissociation of the 50S particle led to the
identiﬁcation of pentamers and hexamers, as well as
monomers, elucidating the structure of the ribo-
some [5]. This paves the way for dynamic studies of
the ribosome’s response to therapeutic agents.
Finally, Dr Robinson mentioned studies of the
yeast spliceosome. This RNA-protein complex has
never been crystallised. By dissecting the subunit
composition, she has obtained useful information
on the stability of the various components, which
should facilitate crystallisation attempts.
GiulioSuperti-Furga (CellZome GmbH, Heidelberg)
has focused on protein complexes in a different
way, exploiting the fact that tyrosine phosphoryla-
tion is almost invariably associated with protein-
protein interactions. Endogenous genes are tagged
in situ then translated. Phosphatase activity is
blocked using vanadate, then the proteins are
immunoprecipitated with an anti-phosphotyrosine
antibody. The proteins are puriﬁed using tandem
afﬁnity puriﬁcation, which is reliable and robust
and can be adapted to high-throughput studies: the
system is now handling 4000 MALDI samples per
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plexes in Saccharomyces cerevisiae. The data are
automatically compared with binary interactions
listed in the Yeast Protein Database; novel com-
ponents are then annotated manually. This is an
ambitious project that had just come on-stream at
the time of the workshop but which should soon be
providing useful information. There are limitations,
as raised in the discussion: for example, this method
will not detect membrane proteins, nor does it say
anything about the stoichiometry or the speciﬁcity
of the interactions. Pierre Legrain pointed out that
researchers see protein interactions in different
ways: geneticists are interested in pathways, linking
proteins in a linear chain of function, whereas
biochemists are interested in complexes that associ-
ate to perform a given task. He also raised the issue
of subcellular localisation: many proteins are active
only within a given cellular compartment and any
interactions detected outside of that compartment
probably bear little relevance to their function. Dr
Superti-Furga acknowledged these caveats but
emphasised that collection of the data is just the
beginning, interpretation of the data will be the real
challenge.
Bioinformatics
The ﬁrst session was concerned with the annota-
tion of genomic and protein databases. Michael
Sternberg (Imperial College, London) is exploiting
the rapidly increasing repository of information
on protein structure to understand more about
structure-function relationships. Integrase and ribo-
nuclease H show very little sequence homology but
have conserved structural homology, particularly
around the active site. Chymotrypsin and subtilisin
perform the same function but use different protein
folds to do so. On the other hand, lysozyme and
a-lactalbumin share almost identical structures but
one is enzymatically active and the other is not.
Automated methods for protein structure predic-
tion are gradually improving, and homology mod-
elling has revealed that most amino acid changes
occur in loops and exposed areas of proteins. When
two proteins show good structural homology, an
automated prediction is nearly as accurate as a
manual one. However, when the homology falls
below 40%, manual input becomes essential.
In Dr Sternberg’s automated analysis, the pro-
gram 3D-JIGSAW (http://www.bmm.icnet.uk/servers/
3djigsaw/) compares the sequence of a query protein
to the templates in their library. If there is no direct
structural ‘hit’, then a fold recognition algorithm,
3D-PSSM (http://www.bmm.icnet.uk/y3dpssm/), is
applied to model the fold using known structural
information, this can detect more remote homo-
logies that PSI-BLAST misses. Dr Sternberg then
takes information on biological function derived
from text searches of the PubMed archive and uses
this to manually rank the target proteins proposed
by 3D-PSSM. Last year, this technique proved the
most efﬁcient in a CASP4 open competition for
determining structures that excluded novel folds. It
could be used to facilitate future drug development,
speciﬁcally in the design of antagonists or inhibitors
to ﬁt into active site pockets.
Thure Etzold (European Bioinformatics Institute)
chose to focus on the problems raised by the
explosion in the amount of protein interaction
data and the need for an integrated solution.
There are many collections of protein interaction
data being assembled and many use their own set of
standards, which in turn are based on different
assumptions. The NCBI developed standards for its
own use that have since been adopted more widely;
ACeDB was developed to store genome data for the
worm Caenorhabditis elegans and was subsequently
expanded for more general use; Array Express is
not a standard, but is a technology that has found
broad application.
Dr Etzold classiﬁed people who build solutions as
generalists or pragmatists: the former focus on
ﬂexible and extensible solutions that are often slow
and do not match the detailed requirements of a
particular task; the latter create a system that does
exactly what is required initially but cannot be
readily adapted and is often short lived. Lion
Biosciences’ solution was to create a network of
databases, the SRS library network, which has
explicit external references, such as a link to a
speciﬁc database, and implicit cross-references, in
the form of common ﬁelds and standard terms
within those ﬁelds, for example, correct taxonomi-
cal terms for organisms and Gene Ontology
nomenclature for genes and their functions. The
problem with this approach is that there are many
sources of error: errors in the databases, changes to
content or format, and differences in concept. The
envisaged solution is a database that has frequent,
automatic and extensive consistency checks. Such
an integrated database would need to enable
scientists to create data viewers, see analysis ﬂows,
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links between them. All of this would need to be
integrated with analysis tools. SRS has a descriptive
language for such extensions but users may perceive
this as additional programming, therefore it
requires a graphical interface.
Peter Roepstorff asked whether, as an extreme
example, a PhD student should be encouraged to
develop a new database or persuaded to use the
existing technology to avoid further confusion.
Thure Etzold replied that new technology is
always needed as the ﬁeld matures and creativity
should be encouraged. As standard tools are more
widely adopted, it becomes easier for new features
to be integrated into existing structures. Pierre
Legrain called for a more systematic gene nomen-
clature: the current system has evolved over 100
years with no clear pattern so that many gene
names do not refer to the primary function of the
gene product. He said that if biologists do not
tackle this problem now, it will be even worse later.
Thure Etzold replied that the Gene Ontology
scheme is making progress in this area.
The second half of the Bioinformatics session
addressed the issue of trying to extract information
on protein interactions from the published literature.
Manuela Helmer Citterich (University of Rome, Tor
Vergata) described iSPOT, a web tool for inferring
protein-protein interactions (see Brannetti et al.,
p. 314), and MINT, a database dedicated to pro-
tein interactions (see Wixon, p. 338). iSPOT does
not need the 3D structure of the domains under
study and can make a prediction as long as their
sequences can be conﬁdently aligned to domains of
known structure from the same families. The
reliability of the prediction depends on the level
of sequence identity between the query domains
and the domains whose experimentally determined
binding data have been used to train the software.
Rita Casadio (University of Bologna) presented a
method for the prediction of protein-protein inter-
action sites, based on neural networks. The aim is
to identify those regions on a protein surface that
interact with other proteins. She used information
from several databases amounting to several thou-
sand known interactions among over 4000 proteins
to look at shape, chemical complementarity, and
the distribution of charged and polar residues but
found no characteristics that typiﬁed protein-
protein interacting surfaces. Such surfaces showed
the same residue composition as other regions of
the proteins.
Dr Casadio examined bacterial luciferase, which
comprises a heterodimer that has been crystallised.
She conceptually dissected the crystal and studied
the interacting surfaces. This process was repeated
for many known examples and the information was
used to ‘train’ a neural network to extract general
rules concerning protein interactions. These were
stored in an algorithm that could, when given
information about a new structure, predict which
parts of the protein were most likely to form the
interface. For a mouse antibody fragment, the
algorithm correctly detected 73% of interacting
residues; although it did miss some and gave a
couple of false positive results. This method could
be useful in complementing results from other
studies in proteomics. However, one drawback in
using data from individual protein structures is that
there may be conformational changes during com-
plex formation.
Jong Park (MRC-Dunn Institute, Cambridge)
believes that the direct interaction space for proteins
is too big (with many millions of possibleinteractions)
for ittobe possibleto globally map them. Heistaking
a different approach, constructing a general protein
interaction map using structural information from the
Protein Data Bank (PDB). By applying a strict
criterion of structural interaction, he is able to
construct a broad and general, but deﬁnite, map. He
deﬁnes a domain arbitrarily, merging structural and
sequence alignment data. He then incorporates phy-
logenetic information on protein family interactions,
and data on fold detection and classiﬁcation. These
datasets are then used to predict interactions among
homologues, but the data have to be validated. The
outcome is PSIMAP (http://www.biointeraction.net/),
which contains information on all known domains.
Dr Park proposes that intra- and intermolecular
interactions are fundamentally different. He states
that protein folds have diverse and distinct reper-
toires of interactions, which should ultimately make
their classiﬁcation simpler, but there is still a long
way to go.
In response to questions, Dr Park conceded that
this method cannot deal with protein interactions
that are mediated by unstructured regions and that
he has not yet examined why interactions bet-
ween certain pairs of folds are favoured. Andreas
Pluckthun pointed out that the immunoglobulin
domain, while stable, is used differently in various
receptors: cellular receptors present the edge of the
domain for binding, whereas antibodies use a more
central part of the domain. Dr Park replied that
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that his method could map the majority of inter-
actions that occur in a general way.
The meeting was closed by Alfonso Valencia
(Protein Design Group, Cantoblanco, Madrid)
who described his work on extracting information
concerning protein interactions from the published
literature (see Blaschke et al., p. 310) and a method
for prediction of protein interactions. The predic-
tion method looks for correlated mutations between
possible interaction partners and also for comple-
mentarity of the phylogenetic trees of potentially
interacting proteins, which could indicate co-
evolution of the proteins.
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